Literature DB >> 15972851

Methylation silencing of the Apaf-1 gene in acute leukemia.

Yutaka Furukawa1, Krittaya Sutheesophon, Taeko Wada, Miki Nishimura, Yasushi Saito, Hideshi Ishii, Yusuke Furukawa.   

Abstract

Apaf-1 is important for tumor suppression and drug resistance because it plays a central role in DNA damage-induced apoptosis. Inactivation of the Apaf-1 gene is implicated in disease progression and chemoresistance of some malignancies. In this study, we attempted to clarify the role of Apaf-1 in leukemogenesis. Apaf-1 mRNA levels were below the detection limit or very low in 5 of 20 human leukemia cell lines (25%) and 5 of 12 primary acute myeloblastic leukemia cells (42%). There were no gross structural abnormalities in the Apaf-1 gene in these samples. Expression of factors regulating Apaf-1 transcription, such as E2F-1, p53, and Sp-1, did not differ between Apaf-1-positive and Apaf-1-negative cells. Methylation of CpG in the region between +87 and +128 of the Apaf-1 gene was almost exclusively observed in Apaf-1-defective cell lines. Treatment of these cells with 5-aza-2'-deoxycytidine, a specific inhibitor of DNA methylation, restored the expression of Apaf-1. Furthermore, we showed that the region between +87 and +128 could act as a repressor element by recruiting corepressors such as methylated DNA-binding domain 2 and histone deacetylase 1 upon methylation. Overexpression of Dnmt1, a mammalian maintenance DNA methyltransferase, was associated with Apaf-1 gene methylation. DNAs from Dnmt1-overexpressing cells were more resistant to digestion with methylation-sensitive enzyme HpaII than those from cells with low Dnmt1 expression, suggesting that Dnmt1 mediates aberrant methylation of multiple genes. In conclusion, methylation silencing is a mechanism of the inactivation of Apaf-1 in acute leukemia, and Dnmt1 overexpression may underlie hypermethylation of the Apaf-1 gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972851     DOI: 10.1158/1541-7786.MCR-04-0105

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  29 in total

1.  Trichostatin A restores Apaf-1 function in chemoresistant ovarian cancer cells.

Authors:  Lijun Tan; Roland P Kwok; Abhishek Shukla; Malti Kshirsagar; Lili Zhao; Anthony W Opipari; J Rebecca Liu
Journal:  Cancer       Date:  2010-10-05       Impact factor: 6.860

2.  Promoter methylation confers kidney-specific expression of the Klotho gene.

Authors:  Masahiro Azuma; Daisuke Koyama; Jiro Kikuchi; Hiromichi Yoshizawa; Dissayabutra Thasinas; Kazuhiro Shiizaki; Makoto Kuro-o; Yusuke Furukawa; Eiji Kusano
Journal:  FASEB J       Date:  2012-07-10       Impact factor: 5.191

Review 3.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 4.  Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?

Authors:  Jennifer K Lue; Jennifer E Amengual; Owen A O'Connor
Journal:  Curr Oncol Rep       Date:  2015-09       Impact factor: 5.075

5.  Methylation of the APAF-1 and DAPK-1 promoter region correlates with progression of renal cell carcinoma in North Indian population.

Authors:  Shiekh Tanveer Ahmad; Wani Arjumand; Amlesh Seth; Ashish Kumar Saini; Sarwat Sultana
Journal:  Tumour Biol       Date:  2011-09-16

6.  Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA.

Authors:  Barbora Brodská; Petra Otevřelová; Aleš Holoubek
Journal:  Mol Cell Biochem       Date:  2010-12-14       Impact factor: 3.396

7.  Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.

Authors:  Warren Fiskus; Kate Buckley; Rekha Rao; Aditya Mandawat; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Peter Atadja; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-05-18       Impact factor: 4.742

8.  Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse.

Authors:  Heike Kroeger; Jaroslav Jelinek; Marcos R H Estécio; Rong He; Kimie Kondo; Woonbok Chung; Li Zhang; Lanlan Shen; Hagop M Kantarjian; Carlos E Bueso-Ramos; Jean-Pierre J Issa
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

9.  Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b.

Authors:  Regina Maushagen; Stefan Reers; Ann-Christin Pfannerstill; Angelina Hahlbrock; Roland Stauber; Ramtin Rahmanzadeh; Dirk Rades; Ralph Pries; Barbara Wollenberg
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-01       Impact factor: 4.553

10.  Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.

Authors:  Nicholas J Achille; Megan Othus; Kathleen Phelan; Shubin Zhang; Kathrine Cooper; John E Godwin; Frederick R Appelbaum; Jerald P Radich; Harry P Erba; Sucha Nand; Nancy J Zeleznik-Le
Journal:  Leuk Res       Date:  2016-01-15       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.